^
    2ms
    Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer (clinicaltrials.gov)
    P2, N=13, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • oleclumab (MEDI9447)
    2ms
    Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial (clinicaltrials.gov)
    P1, N=26, Completed, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Sep 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)
    3ms
    SPRINT 2: The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, Montefiore Medical Center
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)
    4ms
    COLUMBIA 1: COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC (clinicaltrials.gov)
    P1/2, N=61, Active, not recruiting, MedImmune LLC | Terminated --> Active, not recruiting | Trial completion date: Oct 2022 --> Nov 2025
    Enrollment closed • Trial completion date
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • oleclumab (MEDI9447)
    4ms
    PACIFIC-9: A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=1027, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    EGFR wild-type • ALK wild-type
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)
    5ms
    Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial. (PubMed, JAMA Netw Open)
    Novel immunotherapy combinations involving the anti-CD73 monoclonal antibody oleclumab or the anti-NKG2A monoclonal antibody monalizumab have the potential to build on the durvalumab standard of care. This finding supports further investigation of these novel combinations in the phase 3 PACIFIC-9 trial. ClinicalTrials.gov Identifier: NCT03822351.
    Clinical • Journal
    |
    KLRC1 (Killer Cell Lectin Like Receptor C1)
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)
    6ms
    Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase II NeoCOAST-2 trial. (PubMed, Nat Med)
    In the phase II NeoCOAST-2 platform study, 202 patients with untreated, resectable stage IIA-IIIB non-small-cell lung cancer (NSCLC) were randomized to receive neoadjuvant durvalumab plus platinum-doublet chemotherapy with oleclumab, a CD73 inhibitor (Arm 1), or with monalizumab, a NKG2A inhibitor (Arm 2), or neoadjuvant durvalumab plus single-agent platinum chemotherapy with the TROP-2 antibody-drug conjugate (ADC) datopotamab deruxtecan (Arm 4), followed by surgical resection and adjuvant durvalumab with oleclumab or monalizumab (Arms 1 and 2) or durvalumab alone (Arm 4). In NeoCOAST-2, the first neoadjuvant trial examining an ADC plus chemo-immunotherapy in resectable NSCLC, pCR rates were highest in the datopotamab-deruxtecan-containing arm, warranting further investigation in larger trials of ADCs and checkpoint inhibition in the neoadjuvant setting. ClinicalTrials.gov identifier: NCT05061550 .
    P2 data • Journal
    |
    CD73 (5'-Nucleotidase Ecto) • KLRC1 (Killer Cell Lectin Like Receptor C1)
    |
    Imfinzi (durvalumab) • Datroway (datopotamab deruxtecan-dlnk) • oleclumab (MEDI9447) • monalizumab (IPH2201)
    7ms
    Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial (clinicaltrials.gov)
    P1, N=26, Active, not recruiting, National Cancer Institute (NCI) | N=48 --> 26 | Trial completion date: Mar 2025 --> Apr 2026
    Enrollment change • Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)
    7ms
    HUDSON: Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (clinicaltrials.gov)
    P2, N=527, Active, not recruiting, AstraZeneca | Trial primary completion date: Sep 2026 --> Sep 2024
    Trial primary completion date • IO biomarker
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738) • Recentin (cediranib) • oleclumab (MEDI9447) • vistusertib (AZD2014) • danvatirsen (AZD9150)
    8ms
    DOSa: Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (clinicaltrials.gov)
    P2, N=75, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447)
    9ms
    A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA) (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447)
    9ms
    Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study (clinicaltrials.gov)
    P1/2, N=43, Active, not recruiting, MedImmune LLC | Trial completion date: Jul 2025 --> Mar 2026
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    Tagrisso (osimertinib) • oleclumab (MEDI9447) • imaradenant (AZD4635)